Traditional screening of candidate molecules is mainly based on biological activity, while pharmaceutical developability is seldom considered at the molecule discovery stage. Molecules with physical and chemical properties that are not suitable for further pharmaceutical development due to low expression titer, low protein purity, poor stability, or other issues need to be excluded early. Intellective Bio performs a complete set of developability studies such as determination of physicochemical properties, post-translational modification analysis, and stability assessments to help biopharmaceutical innovators focus on candidate molecules that have high biological activity and suitable physicochemical properties for further development.